You are here

Article info

Article menu
Oncolytic and local immunotherapy
Original research
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming

Authors

  • Mark Aleynick Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USAMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Judit Svensson-Arvelund Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Gvantsa Pantsulaia Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Kristy Kim Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Samuel A Rose Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USAMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Ranjan Upadhyay Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USAMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Michael Yellin Celldex Therapeutics Inc, Hampton, New Jersey, USA PubMed articlesGoogle scholar articles
  • Henry Marsh Celldex Therapeutics Inc, Hampton, New Jersey, USA PubMed articlesGoogle scholar articles
  • Daniel Oreper Genentech Inc, South San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Suchit Jhunjhunwala Genentech Inc, South San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Christine Carine Moussion Genentech Inc, South San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Miriam Merad Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Brian D Brown Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles
  • Joshua D Brody Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USAHematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA PubMed articlesGoogle scholar articles

Citation

Aleynick M, Svensson-Arvelund J, Pantsulaia G, et al
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming
Journal for ImmunoTherapy of Cancer 2023;11:e007198. doi: 10.1136/jitc-2023-007198
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.